What is GHK-Cu? The copper peptide explained

What is GHK-Cu?

GHK-Cu is a small peptide bound to a copper ion. The peptide, GHK, is a chain of three amino acids: glycine, histidine and lysine. It was found in human plasma in the 1970s and also occurs in saliva and urine (Pickart et al., BioMed Research International, 2015). In GHK-Cu, one copper(II) ion, which is copper carrying two positive charges, is held by the peptide, and spectroscopy of the complex in solution shows three nitrogen ligands on the copper (Hureau et al., Chemistry, 2011). Chemistry databases list the complex under several names, including prezatide copper and copper tripeptide-1 (PubChem, checked 14 October 2026). GHK-Cu is a research compound, and this page reports what published studies describe.

Your own blood carries the same peptide. A 2018 review quotes age-associated plasma GHK values, and this page did not check the primary measurement or its cohort, so it reports no figure; one of the review's authors held commercial interests in the field for decades (Pickart and Margolina, International Journal of Molecular Sciences, 2018; Najafi et al., 2026). The name GHK follows the three amino acids, and the Cu is copper. The GHK-Cu research guide tells the discovery story in plain English.

GHK sits in the alpha 2(I) chain of type I collagen (Maquart et al., 1988). In cultured fibroblasts, GHK-Cu stimulated collagen synthesis, a cell-culture result whose abstract gives no culture count and that does not establish a human result (Maquart et al., FEBS Letters, 1988).

Is GHK-Cu the same thing as a copper peptide?

GHK-Cu is one copper peptide, but 'copper peptide' names a wider group. A 2026 review in Pharmaceutics separates four things that the literature often treats as one: apo-GHK (GHK without copper), canonical GHK-Cu, GHK-derived copper peptides, and copper-peptide systems built on other sequences (Mateescu et al., 2026). AHK-Cu uses a different sequence, alanyl-histidyl-lysine, and the same review describes it as resting on a thin, poorly characterised evidence base. A product that says 'copper peptide' does not identify which one it holds by that name alone. The table below lists the names.

What does the copper in GHK-Cu do?

A 2001 paper studied copper-complex formation and cell growth in vitro, but its abstract does not identify the cell model or culture count, so this page reports no cell-growth result (Conato et al., Biochimica et Biophysica Acta, 2001). A 2021 chemistry study states that GHK's activity is attributed to the copper-complexed form and describes a transient intermediate when glutathione reduces the copper, a test-tube result that does not establish a human result (Ufnalska et al., Inorganic Chemistry, 2021). A 2026 review discusses a copper-free GHK cell report, but this page did not verify the primary report or its culture details, so no result is reported (Choi et al., 2012, as described by Najafi et al., Archives of Internal Medicine Research, 2026).

Copper cuts both ways. A 2026 review calls labile copper, meaning loosely held copper, the single most consequential attribute in this product class, because it sets the boundary between therapeutic and pro-oxidant behaviour of the same element (Mateescu et al., 2026). The review also notes that total antioxidant assays can obscure pro-oxidant behaviour at higher concentrations.

Is GHK-Cu supposed to be blue?

The sources searched on 14 October 2026 did not find a published specification of the colour of GHK-Cu powder, so 'supposed to be blue' has no published specification behind it in those sources. The catalogue product record describes its freeze-dried GHK-Cu as a blue solid (checked 14 October 2026). Colour is a visual observation, not an identity test. A 2026 review says the term 'GHK-Cu' compresses a dynamic coordination system into a single label, and that the species present depend on pH, stoichiometry and competing ligands (Mateescu et al., Pharmaceutics, 2026). A report that names the compound, the lot and the tests is what documents identity.

The catalogue lists GHK-Cu reference material with the appearance and lot in one record, and states that its historical sample report does not verify the current vial's identity. The guide to reading a certificate of analysis explains what a report covers and what it leaves out.

Evidence limits

What are the downsides of copper peptides?

The evidence itself has limits. Najafi et al. report that about 35% of the primary GHK-Cu literature in their search window includes Pickart or Margolina as an author, and they say this concentration of authorship limits the independence of the evidence base (Najafi et al., 2026). In the 13-person post-laser trial, blinded and computer evaluation found no group difference in redness or wrinkles, while the patient questionnaire favoured GHK-Cu for overall skin quality (P = .04), a small post-laser aftercare trial that does not establish an effect for other skin settings (Miller et al., Archives of Facial Plastic Surgery, 2006). A 2026 review also notes that angiogenesis, meaning new blood-vessel growth, may be undesirable in tumours, proliferative retinopathy (abnormal vessel growth in the eye) and vascular malformations, so that any programme promoting it needs context-specific safety assessment (Mateescu et al., Pharmaceutics, 2026).

What published studies found covers itching, sleep and the human trials one by one.

What have studies tested GHK-Cu for?

Published studies have tested GHK-Cu in wound repair, skin appearance, hair, muscle and gut inflammation, mostly in cells and animals. In 24 rats with ischaemic skin-flap wounds, wound area had decreased by 64.5% with copper tripeptide, 45.6% with vehicle and 28.2% with no treatment by day 13, an animal result that does not establish a human result (Canapp et al., Veterinary Surgery, 2003). In 18 rabbits with full-thickness wounds, mean unhealed wound area was smaller with copper tripeptide than with no treatment on days 7, 14 and 21, an animal result that does not establish a human result (Cangul et al., Veterinary Dermatology, 2006). In mice exposed to cigarette smoke, GHK-Cu reduced muscle mass loss and improved grip strength, a mouse disease-model result whose abstract gives no group sizes and that does not establish a human result (Deng et al., Journal of Cachexia, Sarcopenia and Muscle, 2023). In mice with dextran sulfate sodium colitis, GHK-Cu reduced weight loss and colon shortening, a mouse result whose abstract gives no group sizes and that does not establish a human result (Mao et al., Frontiers in Pharmacology, 2025). The human studies are small: a 13-patient post-laser trial that does not establish an effect for other skin settings (Miller et al., 2006) and a split-face eyebrow trial in 18 healthy adults in which eyebrow hair count and diameter were higher on the GHK-Cu side than the placebo side, a small eyebrow-only trial that does not establish scalp-hair effects (Bo et al., *Procedia of Multidisciplinary Research*, 2026). 'Tested for' is not 'shown to'.

A learning study gave GHK without copper to mice that were then sleep-deprived: the GHK mice did not show the acute learning impairment seen in saline mice, and GHK prevented increases in MCP-1 and nitrotyrosine in the hippocampus, a mouse result from an abstract that gives no group sizes and does not establish a human result (Rosenfeld et al., Aging Pathobiology and Therapeutics, 2023). Each result, with its model and its limits, is on the page of published study findings. A registered Phase 2, randomised, double-blind, vehicle-controlled split-wound trial of GHK-Cu on standardised acute skin wounds in healthy adults, NCT07437586, was listed as recruiting, with no results posted, when checked on 14 October 2026 (ClinicalTrials.gov).

Which forms of GHK-Cu appear in published research?

Published research uses GHK-Cu in several chemical and delivery forms, and the sources searched on 14 October 2026 did not find a human study that ranks them. Chemically, the literature separates free GHK, GHK-Cu and derivatives such as palmitoyl-GHK, which has a fatty-acid chain attached (Mortazavi et al., BioImpacts, 2025; Mateescu et al., Pharmaceutics, 2026). Studies have used creams, gels, serums and liposome formulations (Najafi et al., 2026). A 2026 review did not pool results across studies, because the formulations, active-entity definitions and endpoints were not quantitatively commensurable (Mateescu et al., 2026).

Is GHK-Cu legal in Australia?

This page states no legal status for GHK-Cu. The Peptides and Australian Law page compares twelve catalogue compounds with the October 2026 Poisons Standard (Federal Register of Legislation F2026L01327, commencing 1 October 2026), read on 1 October 2026, and records GHK-Cu as held, which means no status is stated in either direction. Separate rules may apply to a skin-care product that lists copper tripeptide-1, and this page did not check them. The law page names the primary documents.